Serum biomarker is used to detect the irritable bowel syndrome (IBS). No single serum biomarker can reliably differentiate irritable bowel syndrome (IBS) from other functional gastrointestinal disorders or organic diseases of the gastrointestinal tract.
Sepsis, an innate immunological response of systemic inflammation to infection, is a growing problem worldwide with a relatively high mortality rate. Immediate treatment is required, necessitating quick, early and accurate diagnosis. Rapid molecular-based tests have been developed but still suffer some disadvantages. The most commonly studied biomarkers of sepsis are reviewed for their current uses and diagnostic accuracies, including C-reactive protein, procalcitonin, serum amyloid A, mannan and IFN-γ-inducible protein 10, as well as other potentially useful biomarkers.
Related Journals of Serum Biomarkers
Insights in Medical Physics, Journal of Molecular and Genetic Medicine, Clinical & Experimental Pathology, Clinical Case Reports, Journal of Medical Diagnostic Methods, Biomarkers: biochemic, Biomarkers in medicine,The Biomarkers Consortium, Biomarkers, Journal of Biomarkers.